Literature DB >> 18059192

The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo.

Yan-rong Lu1, Yu Yuan, Xiu-jie Wang, Ling-ling Wei, You-nan Chen, Cong Cong, Sheng-fu Li, Dan Long, Wei-dong Tan, Ying-qiu Mao, Jie Zhang, You-ping Li, Jing-qiu Cheng.   

Abstract

Mesenchymal stem cells (MSCs) play an important role in the development and growth of tumor cells. The purpose of this study is to confirm the effect of MSCs on tumor cell growth in vitro and in vivo and to elucidate the mechanism. MSCs were isolated from mouse bone marrow and cocultured with murine hepatoma H22, lymphoma (YAC-1 and EL-4) and rat insulinoma INS-1 cell lines. The growth inhibitory effect of MSCs on tumor cells was tested through MTT and 3H-TdR incorporation assay. The apoptosis induction effect of MSCs on tumor cells was assessed with flow cytometry (FCM) and RT-PCR assay. MSCs were inoculated into BALB/c mice alone or coinoculated with ascitogenous hepatoma cells intraperitonealy, respectively. The tumor growth inhibition of MSCs was investigaed through the incidence and volume of ascites formation, and the immunosuppression effect was studied with splenocyte response to ConA stimulation test and T cell subsets analysis (FCM). The results showed that MSCs exhibited a number-dependent growth inhibitory effect on murine tumor cell lines in vitro and inhibited the growth of ascitogenous hepatoma cells in vivo without host immunosuppression. MSCs could upregulate tumor cells mRNA expression of cell cycle negative regulator p21 and apoptosis associated protease caspase 3. The findings of this experimental study demonstrated that MSCs had potential inhibitory effects on tumor cell growth in vitro and in vivo without host immunosuppression, by inducing apoptotic cell death and G(0)/G(1) phase arrest of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18059192     DOI: 10.4161/cbt.7.2.5296

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  80 in total

Review 1.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

Review 2.  Regenerative therapy after cancer: what are the risks?

Authors:  Vera S Donnenberg; Ludovic Zimmerlin; Joseph Peter Rubin; Albert D Donnenberg
Journal:  Tissue Eng Part B Rev       Date:  2010-11-02       Impact factor: 6.389

3.  Mesenchymal stem cells: Molecular characteristics and clinical applications.

Authors:  Farbod Rastegar; Deana Shenaq; Jiayi Huang; Wenli Zhang; Bing-Qiang Zhang; Bai-Cheng He; Liang Chen; Guo-Wei Zuo; Qing Luo; Qiong Shi; Eric R Wagner; Enyi Huang; Yanhong Gao; Jian-Li Gao; Stephanie H Kim; Jian-Zhong Zhou; Yang Bi; Yuxi Su; Gaohui Zhu; Jinyong Luo; Xiaoji Luo; Jiaqiang Qin; Russell R Reid; Hue H Luu; Rex C Haydon; Zhong-Liang Deng; Tong-Chuan He
Journal:  World J Stem Cells       Date:  2010-08-26       Impact factor: 5.326

Review 4.  Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects.

Authors:  Silvia Berardis; Prenali Dwisthi Sattwika; Mustapha Najimi; Etienne Marc Sokal
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

5.  Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.

Authors:  Ioannis Christodoulou; Maria Goulielmaki; Marina Devetzi; Mihalis Panagiotidis; Georgios Koliakos; Vassilis Zoumpourlis
Journal:  Stem Cell Res Ther       Date:  2018-12-07       Impact factor: 6.832

6.  Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production.

Authors:  Karen McLean; Yusong Gong; Yunjung Choi; Ning Deng; Kun Yang; Shoumei Bai; Lourdes Cabrera; Evan Keller; Laurie McCauley; Kathleen R Cho; Ronald J Buckanovich
Journal:  J Clin Invest       Date:  2011-08       Impact factor: 14.808

7.  Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells.

Authors:  Scott A Bergfeld; Laurence Blavier; Yves A DeClerck
Journal:  Mol Cancer Ther       Date:  2014-02-06       Impact factor: 6.261

8.  Interactions of human MSC with head and neck squamous cell carcinoma cell line PCI-13 reduce markers of epithelia-mesenchymal transition.

Authors:  F Böhrnsen; M Fricke; C Sander; A Leha; H Schliephake; F J Kramer
Journal:  Clin Oral Investig       Date:  2014-10-28       Impact factor: 3.573

Review 9.  Mesenchymal stem cells engineered for cancer therapy.

Authors:  Khalid Shah
Journal:  Adv Drug Deliv Rev       Date:  2011-06-29       Impact factor: 15.470

Review 10.  Stem cell paracrine actions and tissue regeneration.

Authors:  Priya R Baraniak; Todd C McDevitt
Journal:  Regen Med       Date:  2010-01       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.